Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab (CIM331)" Global Phase II Study Data Published in The New England Journal of Medicine Online
Pharmaceutical Co., Ltd.
(TOKYO:4519) announced today that the data
from the global phase II study (the XCIMA study) for the planned
indication of atopic dermatitis (AD) was published in The New England
Journal of Medicine Online on March 2, 2017 (EST). The study was
conducted to evaluate the safety and efficacy of nemolizumab in 264
patients with moderate-to-severe AD, and the safety and efficacy of
nemolizumab at 12 weeks were confirmed.
“Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.,” Thomas Ruzicka, M.D., et al
The efficacy and safety data obtained from a one-year extension of the study will be presented on March 4th at the Late-Breaking Research Forums of the 2017 Annual American Academy of Dermatology (AAD) Meeting which will be held on March 3 to 7 in Orlando, Florida, USA.
“Control of pruritus is crucial for AD patients. It is directly related to their quality of life,” said Dr. Yasushi Ito, Senior Vice President, Head of Project & Lifecycle Management Unit. “This data emphasizes the importance of controlling IL-31 in AD. It also indicates that nemolizumab, an anti-IL-31 antibody, may offer a promising treatment option for the disease. Chugai will closely work together with its partners - Galderma and Maruho, toward helping AD patients by offering this new treatment option as early as possible.”
“Nemolizumab is the first drug specifically targeting pruritus. Its use is very convenient to patients with one subcutaneous injection per month,” said, Professor Thomas Ruzicka, Ludwig-Maximilian University Munich, the first author of the article. “Since IL-31 is involved in a variety of other pruritic skin diseases, the innovative drug has a large potential in dermatology.”
Chugai granted the exclusive development and marketing rights of
nemolizumab worldwide, excluding Japan and Taiwan to Galderma and
licensed out the development and marketing rights in the skin disease
area to Maruho for the Japanese market respectively.
Please refer to the press release for the details of the license agreement with
[Overview of the study]
264 patients were randomized to one of the four nemolizumab dose groups (0.1, 0.5, 2.0 mg/kg every 4 week (Q4W) or 2.0 mg/kg every 8 week) or placebo group (Q4W) in the ratio of 1:1:1:1:1. The primary endpoint of the study showed significant improvement of the change in pruritus VAS at 12 weeks compared with placebo with the score of -43.7% for nemolizumab 0.1 mg/kg Q4W, -59.8% for nemolizumab 0.5 mg/kg Q4W, -63.1% for nemolizumab 2.0 mg/kg Q4W and -20.9% for placebo Q4W (p<0.01 12 for all comparisons). the secondary endpoint was change in easi at week of −23.0%, −42.3%, and −40.9% nemolizumab 0.1, 0.5 2.0 mg kg q4w groups, respectively, versus −26.6% placebo. another endpoint, proportion (%) patients with ≥2-point improvement siga 13.8%, 37.5%, 25.1% compared 10.5%> The most common adverse events (AEs) were the exacerbation of AD, nasopharyngitis, upper respiratory tract infections, peripheral edema, and increased creatine phosphokinase. 15 patients experienced AEs related discontinuations and 10 out of 15 were due to AEs related to AD (such as exacerbation of AD and dermatitis exfoliativa). 0.01>
About nemolizumab (CIM331)
A humanized anti-human IL-31 receptor A (IL-31RA) monoclonal antibody. IL-31 is identified as a cytokine that can induce pruritus, and reported to be associated with pruritus in atopic dermatitis and dialysis patients. Nemolizumab works by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.
About pruritus VAS
Pruritus VAS stands for pruritus visual analogue scale, by which the severity of pruritus is measured with a 10 cm scale on which patients draw a line to express their assessment of severity (0: no itch, 10: worst imaginable itch).
EASI (Eczema Area and Severity Index) is a tool to demonstrate severity of dermatitis with score from 0 to 72.
sIGA (static Investigator’s Global Assessment) is a tool to evaluate overall severity of dermatitis with a six-level scale from 0 to 5 (0: clear, 5: very severe).
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DELTICOM/YOURTYRES.CO.UK16.3.2018 15:13 | pressemeddelelse
Summer Business with Yourtyres.co.uk: New Shop Feature and High-Performance Tyre Models
NJ-SAMSUNG-ELECTRONICS16.3.2018 13:02 | pressemeddelelse
Available Now: The Smartphone Made for the Way We Communicate Today, the Galaxy S9 and S9+
CONQUEST-GROUP16.3.2018 10:02 | pressemeddelelse
CONQUEST Group Announced the Expansion of its Asset Management Business with the Appointment of Philippe Taillardat to the Role of Director
ACCELSTOR16.3.2018 10:02 | pressemeddelelse
AccelStor All-Flash Solutions Unlock Data Possibilities for AI and Cloud
PA-WESTINGHOUSE-ELECTRIC16.3.2018 09:47 | pressemeddelelse
Westinghouse Completes First Major Decommissioning Work at a Nordic Commercial Nuclear Reactor
SEOUL-SEMICONDUCTOR16.3.2018 09:04 | pressemeddelelse
Lighting Manufacturer LTS Licht & Leuchten, Part of the Fargerhult Group, to Offer Selected Spot- & Downlights with Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum